Phase 1 N=20 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
Pancreatic Cancer
Primary: Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas — 1000 mg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
Type2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 90.8; 96.5; 6.0; 6.6 ng/mL
Phase 1 N=468 A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
Influenza, Human
Primary: Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose Administration — 1; 3; 2; 2 Participants
Phase 1 N=27 T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Lymphoma, B-Cell · Lymphoma, Non-hodgkins
Primary: Percentage of Enrolled Participants Who Actually Get Treated — 76.9 percentage of participants
Phase 1 N=74 Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults
Healthy Male Adults
Primary: Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1 — 18.8; 16.9 ng/mL
Phase 1 N=30 A Multiple Dose Study of MK-3614 (MK-3614-002)
Hypertension
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 4; 3; 4; 3 Participants
Phase 1 N=34 Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
Dry Eye
Primary: Presence of Adverse Events (AEs) — 7; 8 Participants — p=0.409
Phase 1 N=40 DPP4 Inhibition & Beta Cell Function
Healthy
Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05
Phase 1 N=191 Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Solid Tumor
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 59; 20; 21; 21 Participants
Phase 1 N=15 A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 12; 2 Participants
Phase 1 N=74 A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males
Hypogonadism
Primary: Corrected Area Under The Serum Concentration-time Profile From Time 0 to The Last Quantifiable Concentration (AUClast) of Total Testosterone (Part 1). — 1444; 1362…
Phase 1 N=76 H1N1v Virus Challenge Study in Healthy Subjects
Influenza
Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…
Phase 1 N=25 Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
Type 2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 176.1; 133.7 ng/mL
Phase 1 N=6 A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants
Healthy Volunteers
Primary: Period 1: Percent Absolute Bioavailability (%F) for TAK-831 — 17.34 percent absolute bioavailability
Phase 1 N=18 Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of GDC-9545 — 126; 129; 102 nanograms per millilitre (ng/mL)